Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects
Open Access
- 1 July 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (1) , 137-140
- https://doi.org/10.1086/588794
Abstract
Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its useKeywords
This publication has 7 references indexed in Scilit:
- Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo CorrelationThe Journal of Clinical Pharmacology, 2008
- Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid–liquid extraction and HPLC-MS/MSJournal of Chromatography B, 2007
- Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase EnzymeDrug Metabolism and Disposition, 2007
- Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy SubjectsClinical Pharmacology & Therapeutics, 2007
- Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialThe Lancet, 2007
- IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATIONDrug Metabolism and Disposition, 2005